A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who ...

U.S health officials are updating the prescribing labels of long-acting ADHD medications to carry new warnings for children ...

The FDA has issued an alert about a potentially high-risk issue involving Abiomed’s Automated Impella Controller, which is used with the company’s blood pump systems. Abiomed, now part of Johnson & ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

Regeneron Pharmaceuticals gains FDA approval for Lynozyfic drug targeting multiple myeloma, with launch details and executive ...

Since the first-generation CAR-Ts reached the market several years ago, clinicians have become more adept at handling ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...